These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 25778749)

  • 1. Proof-of-Principle for Immune Control of Global HIV-1 Reactivation In Vivo.
    Smith NM; Mlcochova P; Watters SA; Aasa-Chapman MM; Rabin N; Moore S; Edwards SG; Garson JA; Grant PR; Ferns RB; Kashuba A; Mayor NP; Schellekens J; Marsh SG; McMichael AJ; Perelson AS; Pillay D; Goonetilleke N; Gupta RK
    Clin Infect Dis; 2015 Jul; 61(1):120-8. PubMed ID: 25778749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reactivation Kinetics of HIV-1 and Susceptibility of Reactivated Latently Infected CD4+ T Cells to HIV-1-Specific CD8+ T Cells.
    Walker-Sperling VE; Cohen VJ; Tarwater PM; Blankson JN
    J Virol; 2015 Sep; 89(18):9631-8. PubMed ID: 26178987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
    Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
    J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.
    Ensoli B; Nchabeleng M; Ensoli F; Tripiciano A; Bellino S; Picconi O; Sgadari C; Longo O; Tavoschi L; Joffe D; Cafaro A; Francavilla V; Moretti S; Pavone Cossut MR; Collacchi B; Arancio A; Paniccia G; Casabianca A; Magnani M; Buttò S; Levendal E; Ndimande JV; Asia B; Pillay Y; Garaci E; Monini P;
    Retrovirology; 2016 Jun; 13(1):34. PubMed ID: 27277839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TLR1/2 Agonist Enhances Reversal of HIV-1 Latency and Promotes NK Cell-Induced Suppression of HIV-1-Infected Autologous CD4
    Duan S; Xu X; Wang J; Huang L; Peng J; Yu T; Zhou Y; Cheng K; Liu S
    J Virol; 2021 Aug; 95(17):e0081621. PubMed ID: 34133900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Toll-Like Receptor 9 Agonist, MGN1703, Enhances HIV-1 Transcription and NK Cell-Mediated Inhibition of HIV-1-Infected Autologous CD4+ T Cells.
    Offersen R; Nissen SK; Rasmussen TA; Østergaard L; Denton PW; Søgaard OS; Tolstrup M
    J Virol; 2016 May; 90(9):4441-4453. PubMed ID: 26889036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Spontaneous Control of HIV-1 Is Related to Low Frequency of Infected Cells and Inefficient Viral Reactivation.
    Noel N; Peña R; David A; Avettand-Fenoel V; Erkizia I; Jimenez E; Lecuroux C; Rouzioux C; Boufassa F; Pancino G; Venet A; Van Lint C; Martinez-Picado J; Lambotte O; Sáez-Cirión A; Prado JG
    J Virol; 2016 Jul; 90(13):6148-6158. PubMed ID: 27122576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.
    Zaccarelli-Filho CA; Ono E; Machado DM; Brunialti M; Succi RC; Salomão R; Kallás EG; de Moraes-Pinto MI
    Cytometry B Clin Cytom; 2007 Jan; 72(1):14-21. PubMed ID: 17041945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antigen Production After Latency Reversal and Expression of Inhibitory Receptors in CD8+ T Cells Limit the Killing of HIV-1 Reactivated Cells.
    Ruiz A; Blanch-Lombarte O; Jimenez-Moyano E; Ouchi D; Mothe B; Peña R; Galvez C; Genescà M; Martinez-Picado J; Goulder P; Barnard R; Howell B; Clotet B; Prado JG
    Front Immunol; 2018; 9():3162. PubMed ID: 30723480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia.
    Zaunders JJ; Cunningham PH; Kelleher AD; Kaufmann GR; Jaramillo AB; Wright R; Smith D; Grey P; Vizzard J; Carr A; Cooper DA
    J Infect Dis; 1999 Aug; 180(2):320-9. PubMed ID: 10395845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toll-Like Receptor 7 Agonist GS-9620 Induces HIV Expression and HIV-Specific Immunity in Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy.
    Tsai A; Irrinki A; Kaur J; Cihlar T; Kukolj G; Sloan DD; Murry JP
    J Virol; 2017 Apr; 91(8):. PubMed ID: 28179531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged control of replication-competent dual- tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy.
    Salgado M; Rabi SA; O'Connell KA; Buckheit RW; Bailey JR; Chaudhry AA; Breaud AR; Marzinke MA; Clarke W; Margolick JB; Siliciano RF; Blankson JN
    Retrovirology; 2011 Dec; 8():97. PubMed ID: 22141397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Productive human immunodeficiency virus type 1 infection in peripheral blood predominantly takes place in CD4/CD8 double-negative T lymphocytes.
    Kaiser P; Joos B; Niederöst B; Weber R; Günthard HF; Fischer M
    J Virol; 2007 Sep; 81(18):9693-706. PubMed ID: 17609262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short Intracellular HIV-1 Transcripts as Biomarkers of Residual Immune Activation in Patients on Antiretroviral Therapy.
    Ishizaka A; Sato H; Nakamura H; Koga M; Kikuchi T; Hosoya N; Koibuchi T; Nomoto A; Kawana-Tachikawa A; Mizutani T
    J Virol; 2016 Jun; 90(12):5665-5676. PubMed ID: 27030274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of human immunodeficiency virus (HIV)-specific T-cell immunity in control of dual HIV-1 and HIV-2 infection.
    Zheng NN; McElrath MJ; Sow PS; Hawes SE; Diallo-Agne H; Stern JE; Li F; Mesher AL; Robinson AD; Gottlieb GS; Huang Y; Kiviat NB
    J Virol; 2007 Sep; 81(17):9061-71. PubMed ID: 17582003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delayed virus-specific CD8+ cytotoxic T lymphocyte activity in an HIV-infected individual with high CD4+ cell counts: correlations with various parameters of disease progression.
    Dalod M; Fiorentino S; Delamare C; Rouzioux C; Sicard D; Guillet JG; Gomard E
    AIDS Res Hum Retroviruses; 1996 Apr; 12(6):497-506. PubMed ID: 8679305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4(+) T cells from HIV-1-infected HAART-treated patients.
    Bouchat S; Gatot JS; Kabeya K; Cardona C; Colin L; Herbein G; De Wit S; Clumeck N; Lambotte O; Rouzioux C; Rohr O; Van Lint C
    AIDS; 2012 Jul; 26(12):1473-82. PubMed ID: 22555163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Notwithstanding Circumstantial Alibis, Cytotoxic T Cells Can Be Major Killers of HIV-1-Infected Cells.
    Gadhamsetty S; Coorens T; de Boer RJ
    J Virol; 2016 Aug; 90(16):7066-7083. PubMed ID: 27226367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly active antiretroviral therapy results in HIV type 1 suppression in lymph nodes, increased pools of naive T cells, decreased pools of activated T cells, and diminished frequencies of peripheral activated HIV type 1-specific CD8+ T cells.
    Gray CM; Lawrence J; Ranheim EA; Vierra M; Zupancic M; Winters M; Altman J; Montoya J; Zolopa A; Schapiro J; Haase AT; Merigan TC
    AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1357-69. PubMed ID: 11018855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting HIV Reservoir in Infected CD4 T Cells by Dual-Affinity Re-targeting Molecules (DARTs) that Bind HIV Envelope and Recruit Cytotoxic T Cells.
    Sloan DD; Lam CY; Irrinki A; Liu L; Tsai A; Pace CS; Kaur J; Murry JP; Balakrishnan M; Moore PA; Johnson S; Nordstrom JL; Cihlar T; Koenig S
    PLoS Pathog; 2015; 11(11):e1005233. PubMed ID: 26539983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.